Oculis (NASDAQ:OCS) Stock Price Up 4% – Still a Buy?

Oculis Holding AG (NASDAQ:OCS)’s stock price was up 4% on Thursday . The stock traded as high as $19.34 and last traded at $19.49. Approximately 34,697 shares were traded during trading, a decline of 24% from the average daily volume of 45,579 shares. The stock had previously closed at $18.74.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on OCS shares. Chardan Capital restated a “buy” rating and set a $28.00 price target on shares of Oculis in a report on Thursday, March 13th. Robert W. Baird increased their target price on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th. Finally, HC Wainwright reduced their target price on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

Oculis Stock Up 4.5 %

The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $20.96 and a 200-day moving average price of $17.11. The firm has a market cap of $855.34 million, a P/E ratio of -10.15 and a beta of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. On average, equities analysts forecast that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new stake in Oculis during the fourth quarter valued at about $389,000. Bank of America Corp DE raised its stake in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after purchasing an additional 10,667 shares during the last quarter. Bellevue Group AG purchased a new position in shares of Oculis in the fourth quarter worth about $170,000. XTX Topco Ltd purchased a new position in shares of Oculis in the fourth quarter worth about $225,000. Finally, Geode Capital Management LLC raised its stake in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after purchasing an additional 1,800 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.